% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ringborg:170609,
      author       = {U. Ringborg and A. Berns and J. E. Celis and M. Heitor and
                      J. Tabernero and J. Schüz and M. Baumann$^*$ and R.
                      Henrique and M. Aapro and P. Basu and R. Beets-Tan and B.
                      Besse and F. Cardoso and F. Carneiro and G. van den Eede and
                      A. Eggermont and S. Fröhling$^*$ and S. Galbraith and E.
                      Garralda and D. Hanahan and T. Hofmarcher and B. Jönsson
                      and O. Kallioniemi and M. Kásler and E. Kondorosi and J.
                      Korbel and D. Lacombe and J. Carlos Machado and J. M.
                      Martin-Moreno and F. Meunier and P. Nagy and P. Nuciforo and
                      S. Oberst and J. Oliveiera and M. Papatriantafyllou and W.
                      Ricciardi and A. Roediger and B. Ryll and R. Schilsky and G.
                      Scocca and R. Seruca and M. Soares and K. Steindorf$^*$ and
                      V. Valentini and E. Voest and E. Weiderpass and N. Wilking
                      and A. Wren and L. Zitvogel},
      title        = {{T}he {P}orto {E}uropean {C}ancer {R}esearch {S}ummit
                      2021.},
      journal      = {Molecular oncology},
      volume       = {15},
      number       = {10},
      issn         = {1878-0261},
      address      = {Hoboken, NJ},
      publisher    = {John Wiley $\&$ Sons, Inc.},
      reportid     = {DKFZ-2021-02043},
      pages        = {2507-2543},
      year         = {2021},
      note         = {2021 Oct;15(10):2507-2543},
      abstract     = {Key stakeholders from the cancer research continuum met in
                      May 2021 at the European Cancer Research Summit in Porto to
                      discuss priorities and specific action points required for
                      the successful implementation of the European Cancer Mission
                      and Europe's Beating Cancer Plan (EBCP). Speakers presented
                      a unified view about the need to establish high-quality,
                      networked infrastructures to decrease cancer incidence,
                      increase the cure rate, improve patient's survival and
                      quality of life, and deal with research and care
                      inequalities across the European Union (EU). These
                      infrastructures, featuring Comprehensive Cancer Centres
                      (CCCs) as key components, will integrate care, prevention
                      and research across the entire cancer continuum to support
                      the development of personalized/precision cancer medicine in
                      Europe. The three pillars of the recommended European
                      infrastructures - namely translational research,
                      clinical/prevention trials and outcomes research - were
                      pondered at length. Speakers addressing the future needs of
                      translational research focused on the prospects of
                      multiomics assisted preclinical research, progress in
                      Molecular and Digital Pathology, immunotherapy, liquid
                      biopsy and science data. The clinical/prevention trial
                      session presented the requirements for next-generation,
                      multicentric trials entailing unified strategies for patient
                      stratification, imaging, and biospecimen acquisition and
                      storage. The third session highlighted the need for
                      establishing outcomes research infrastructures to cover
                      primary prevention, early detection, clinical effectiveness
                      of innovations, health-related quality-of-life assessment,
                      survivorship research and health economics. An important
                      outcome of the Summit was the presentation of the Porto
                      Declaration, which called for a collective and committed
                      action throughout Europe to develop the cancer research
                      infrastructures indispensable for fostering innovation and
                      decreasing inequalities within and between member states.
                      Moreover, the Summit guidelines will assist decision making
                      in the context of a unique EU-wide cancer initiative that,
                      if expertly implemented, will decrease the cancer death toll
                      and improve the quality of life of those confronted with
                      cancer, and this is carried out at an affordable cost.},
      keywords     = {Cancer Mission (Other) / cancer research/care/prevention
                      continuum (Other) / clinical/prevention trials (Other) /
                      comprehensive cancer centres (Other) / infrastructures for
                      translational cancer research (Other) / outcomes research
                      (Other) / science policy (Other)},
      cin          = {E220 / C110 / B340},
      ddc          = {610},
      cid          = {I:(DE-He78)E220-20160331 / I:(DE-He78)C110-20160331 /
                      I:(DE-He78)B340-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34515408},
      doi          = {10.1002/1878-0261.13078},
      url          = {https://inrepo02.dkfz.de/record/170609},
}